Ignite Creation Date:
2024-05-05 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00241514
Status:
COMPLETED
Last Update Posted:
2011-01-21
First Post:
2005-10-18
Brief Title:
Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Efficacy of Esomeprazole 40 mg Once Daily Versus Placebo or Esomeprazole 20 mg Once Daily Versus Placebo in Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs
Status:
COMPLETED
Status Verified Date:
2011-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study was a multicentre double-blind randomised placebo-controlled parallel group study consisting of 4 visits over a period of 6 months The primary variable was to assess the efficacy of esomeprazole 40 mg orally qd E40 or esomeprazole 20 mg orally qd E20 versus placebo orally qd after 6 months of treatment for the prevention of relapse of upper GI symptoms associated with NSAID use including COX-2 selective NSAIDs in patients receiving daily NSAID therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SH-NEN-0002 | None | None | None |